CBS 2019
CBSMD教育中心
中 文

双重抗血小板治疗持续时间

Abstract

Recommended Article

Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial A randomized comparison of Coronary Stents according to Short or Prolonged durations of Dual Antiplatelet Therapy in patients with Acute Coronary Syndromes: a pre-specified analysis of the SMART-DATE trial Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment Elaborately Engineering a Self-Indicating Dual-Drug Nanoassembly for Site-Specific Photothermal-Potentiated Thrombus Penetration and Thrombolysis
|<<... 5 6 7 8 9 10 11 12 >>|

JOURNAL：CBS2017 Article Link

PADN Presented at ESC2017

CBS2017



Barcelona, Spain---European Society of Cardiology (ESC) , opened its annual congress to great fanfare at local time 8:30am on 28 August. Over 30,000 medical experts and practitioners are gathering together to Barcelona. The ESC is a world leading not-for-profit medical society in the discovery and dissemination of best practices in cardiovascular medicine. Until now, ESC unites 95,000 experts from 56 National Cardiac Societies, 46 cardiovascular ESC sub-specialty communities and 27 Affiliated Cardiac Societies around the world.




On the first day, ESC released guidelines in four clinical relevant domains: 2017 Focused update on Dual Antiplatelet Therapy (DAPT）; Management of Acute Myocardial Infarction in patients presenting with ST-segment elevation; Diagnosis and Treatment of Peripheral Arterial Diseases and Management of Valvular Heart Disease.




With low cure rate, high mortality rate and high therapy costs, pulmonary hypertension(PAH) is still a global public health issue. Some patients cannot benefit from standard medication therapy, even using multi target therapy. It is urgent to find another way than pharmacological treatment to solve more valuable lives. Prof Shaoliang Chen proposed innovatively pulmonary artery denervation in 2013 and presented their successful results from pre-clinical study to clincial study on the 27th at ESC2017.




From 9am to 10am on 28 August, the third day of ESC congress, Prof Chen will present another anticipated topic "coronary intervention" in ESC symposium 26!




This time, all ESC attendees could get further information at the conference site about CBS2017 which will begin on 30 November in Nanjing, China. As a frontier of left main and coronary bifurcation lesions, we sincerely welcome global cardiologists and experts come to Nanjing to share your new ideas and techniques for a better world.




>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top